QRX001

QRX001 is an investigational, single‑use transdermal patch being developed by Quoin Pharmaceuticals as a non‑opioid analgesic for the management of acute post‑operative pain, with the goal of providing up to 72 hours of effective analgesia while significantly reducing or eliminating the need for systemic opioid therapy. Public pipeline summaries describe it as a small‑molecule N‑methyl‑D‑aspartate (NMDA) receptor antagonist formulation, positioned as an alternative to standard opioid‑based post‑surgical pain regimens and as part of Quoin’s broader strategy to offer safer, abuse‑deterrent or opioid‑sparing pain treatments.[1][4][10][13][19]